Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 16/20 | 0.41 |
| ▸ | CTSS | P25774 | 16/20 | 0.41 |
| ▸ | CTSK | P43235 | 16/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485378 | 0.91 | EPHX2 (0.38) | CTSLCTSSCTSKEPHX2NPC1 | |
| SCHEMBL6476464 | 0.89 | EPHX2 (0.36) | CTSLCTSSCTSKEPHX2NPC1 | |
| SCHEMBL6476739 | 0.88 | CCR2 (0.37) | CTSLCTSSCTSKEPHX2NPC1 | |
| SCHEMBL6483202 | 0.87 | CTSL (0.43) | CTSLCTSSCTSKNAAA | |
| SCHEMBL6475393 | 0.83 | CTSL (0.42) | CTSLCTSSCTSKNPC1RAB9A | |
| SCHEMBL6485087 | 0.80 | NAAA (0.36) | CTSLCTSSCTSKEPHX2NPC1 | |
| SCHEMBL6484120 | 0.79 | CTSL (0.42) | CTSLCTSSCTSKNPC1RAB9A | |
| SCHEMBL6476946 | 0.78 | CTSL (0.42) | CTSLCTSSCTSKNPC1RAB9A | |
| SCHEMBL6476449 | 0.77 | RAB9A (0.36) | CTSLCTSSCTSKNPC1RAB9A | |
| SCHEMBL6486966 | 0.77 | HPGD (0.39) | CTSLCTSSCTSKEPHX2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | claimed |
| EP-1413580-A1 | Furanone derivatives as inhibitors of Cathepsin S | Medivir UK Ltd (GB) | 2004-04-28 | — | — | EP | claimed |
| EP-1178986-B1 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LTD (GB) | 2004-02-25 | — | — | EP | claimed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | claimed |
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | disclosed |
| EP-1413580-A1 | Furanone derivatives as inhibitors of Cathepsin S | Medivir UK Ltd (GB) | 2004-04-28 | — | — | EP | disclosed |
| EP-1178986-B1 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020588-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | CTSL 11/4885CTSS 1/4885CTSK 4/4885 |
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | CTSL 11/4885CTSS 1/4885CTSK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.